Related Experiment Videos
Growth factor analysis of low-grade glioma CSF: PDGF and VEGF are not detectable
Abstract:
Platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF-2) are involved in the development of grade 2 gliomas. The aim of the present study was to determine the presence of these growth factors in the cerebrospinal fluid (CSF) and to assess their usefulness as biological markers. CSF was collected from 7 adult patients with newly diagnosed supratentorial low-grade gliomas by lumbar puncture and was analysed together with matched serum samples using radioreceptor and enzyme-linked immunosorbant assays. Neither PDGF nor VEGF were detected in the CSF, and FGF-2 was measurable at extremely low concentrations in only 2 of 7 patients. Serum levels were within normal limits. We conclude that these growth factors are not released into the CSF in any significant amounts and are therefore not suitable as biological markers in grade 2 gliomas.
Insights
Platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and fibroblast growth factor 2 (FGF-2) are not significantly present in cerebrospinal fluid (CSF). Therefore, these growth factors are unsuitable as biomarkers for grade 2 gliomas.
Area of Science:
- Neuro-oncology
- Biomarker discovery
- Cerebrospinal fluid analysis
Background:
- Platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and fibroblast growth factor 2 (FGF-2) play roles in the development of grade 2 gliomas.
- Identifying reliable biomarkers for low-grade gliomas is crucial for diagnosis and monitoring.
Purpose of the Study:
- To determine the presence of PDGF, VEGF, and FGF-2 in cerebrospinal fluid (CSF) of patients with newly diagnosed supratentorial low-grade gliomas.
- To assess the potential of these growth factors as CSF biomarkers for grade 2 gliomas.
Main Methods:
- CSF and matched serum samples were collected from 7 adult patients with newly diagnosed supratentorial low-grade gliomas.
- Radioreceptor and enzyme-linked immunosorbent assays were used to analyze growth factor concentrations.
Main Results:
- PDGF and VEGF were undetectable in the CSF samples.
- FGF-2 was detected at extremely low concentrations in only 2 out of 7 patients.
- Serum levels of these growth factors were within normal ranges.
Conclusions:
- PDGF, VEGF, and FGF-2 are not released in significant amounts into the CSF in grade 2 gliomas.
- These growth factors are not suitable as CSF-based biomarkers for the studied glioma type.